As the COVID-19 pandemic unfolded in 2020, life science as an industry faced huge pressures to develop a vaccine effective against SARS-CoV-2. Medicago played an important role in the global production of the vaccine by providing large amounts of lentil-based lectin for research and development. Lentils synthesize a protein essential to the purification procedures in the vaccine against COVID-19.
A history of fighting diseases
Long before SARS-CoV-2 began making its way around the globe, Medicago produced lectins for vaccine development efforts against earlier waves of swine flu and ebola pathogens. Medicago's grace under such pressure, honed during previous epidemics, enabled delivery of high-quality products reliably even during especially critical periods of the corona pandemic.
Extensive lectin experience
Since its foundation, Medicago has been a major global supplier of lectins. Medicago deftly provided large volumes of Lens culinaris lectin (LCA/LcH), a protein extracted from green lentils and extensively in purification schemes for protein-based corona vaccines. Early on, Medicago also expanded its production capacity to meet what was projected to be a large demand.
High proportions of active molecules
Lectin quality steers a vaccine quality. Medicago is well-known for the superior performances of its lectins in their respective applications. Our entire production chain is quality assured and closely monitored from processing of raw materials to delivery of finished products. Medicago’s high-quality affinity chromatography, which generates a very high active vs. inactive molecule ratio, is a defining feature of lectins capable of ensuring efficient vaccine purification.
Copyright © 2023 Medicago AB
